Cargando…
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel
BACKGROUND: Diabetic nephropathy is a common diabetes mellitus complication associated with hypertension, proteinuria, and excretion of urinary plasmin that activates the epithelial sodium channel, ENaC, in vitro. Here we hypothesized that the deletion of plasminogen and amiloride treatment protect...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763785/ https://www.ncbi.nlm.nih.gov/pubmed/33215566 http://dx.doi.org/10.1161/JAHA.120.016387 |
_version_ | 1783628100837310464 |
---|---|
author | Andersen, Henrik Hansen, Maria Høj Buhl, Kristian B. Stæhr, Mette Friis, Ulla G. Enggaard, Camilla Supramaniyam, Shanya Lund, Ida K. Svenningsen, Per Hansen, Pernille B. L. Jensen, Boye L. |
author_facet | Andersen, Henrik Hansen, Maria Høj Buhl, Kristian B. Stæhr, Mette Friis, Ulla G. Enggaard, Camilla Supramaniyam, Shanya Lund, Ida K. Svenningsen, Per Hansen, Pernille B. L. Jensen, Boye L. |
author_sort | Andersen, Henrik |
collection | PubMed |
description | BACKGROUND: Diabetic nephropathy is a common diabetes mellitus complication associated with hypertension, proteinuria, and excretion of urinary plasmin that activates the epithelial sodium channel, ENaC, in vitro. Here we hypothesized that the deletion of plasminogen and amiloride treatment protect against hypertension in diabetes mellitus. METHODS AND RESULTS: Male plasminogen knockout (plasminogen‐deficient [Plg(−/−)]) and wild‐type mice were rendered diabetic with streptozotocin. Arterial blood pressure was recorded continuously by indwelling catheters before and during 10 days of angiotensin II infusion (ANGII; 30–60 ng/kg per minute). The effect of amiloride infusion (2 mg/kg per day, 4 days) was tested in wild‐type, diabetic ANGII‐treated mice. Streptozotocin increased plasma and urine glucose concentrations and 24‐hour urine albumin and plasminogen excretion. Diabetic Plg(−/−) mice displayed larger baseline albuminuria and absence of urine plasminogen. Baseline mean arterial blood pressure did not differ between groups. Although ANGII elevated blood pressure in wild‐type, diabetic wild‐type, and Plg(−/−) control mice, ANGII did not change blood pressure in diabetic Plg(−/−) mice. Compared with ANGII infusion alone, wild‐type ANGII‐infused diabetic mice showed blood pressure reduction upon amiloride treatment. There was no difference in plasma renin, ANGII, aldosterone, tissue prorenin receptor, renal inflammation, and fibrosis between groups. Urine from wild‐type mice evoked larger amiloride‐sensitive current than urine from Plg(−/−) mice with or without diabetes mellitus. Full‐length γ‐ENaC and α‐ENaC subunit abundances were not changed in kidney homogenates, but the 70 kDa γ‐ENaC cleavage product was increased in diabetic versus nondiabetic mice. CONCLUSIONS: Plasmin promotes hypertension in diabetes mellitus with albuminuria likely through the epithelial sodium channel. |
format | Online Article Text |
id | pubmed-7763785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77637852020-12-28 Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel Andersen, Henrik Hansen, Maria Høj Buhl, Kristian B. Stæhr, Mette Friis, Ulla G. Enggaard, Camilla Supramaniyam, Shanya Lund, Ida K. Svenningsen, Per Hansen, Pernille B. L. Jensen, Boye L. J Am Heart Assoc Original Research BACKGROUND: Diabetic nephropathy is a common diabetes mellitus complication associated with hypertension, proteinuria, and excretion of urinary plasmin that activates the epithelial sodium channel, ENaC, in vitro. Here we hypothesized that the deletion of plasminogen and amiloride treatment protect against hypertension in diabetes mellitus. METHODS AND RESULTS: Male plasminogen knockout (plasminogen‐deficient [Plg(−/−)]) and wild‐type mice were rendered diabetic with streptozotocin. Arterial blood pressure was recorded continuously by indwelling catheters before and during 10 days of angiotensin II infusion (ANGII; 30–60 ng/kg per minute). The effect of amiloride infusion (2 mg/kg per day, 4 days) was tested in wild‐type, diabetic ANGII‐treated mice. Streptozotocin increased plasma and urine glucose concentrations and 24‐hour urine albumin and plasminogen excretion. Diabetic Plg(−/−) mice displayed larger baseline albuminuria and absence of urine plasminogen. Baseline mean arterial blood pressure did not differ between groups. Although ANGII elevated blood pressure in wild‐type, diabetic wild‐type, and Plg(−/−) control mice, ANGII did not change blood pressure in diabetic Plg(−/−) mice. Compared with ANGII infusion alone, wild‐type ANGII‐infused diabetic mice showed blood pressure reduction upon amiloride treatment. There was no difference in plasma renin, ANGII, aldosterone, tissue prorenin receptor, renal inflammation, and fibrosis between groups. Urine from wild‐type mice evoked larger amiloride‐sensitive current than urine from Plg(−/−) mice with or without diabetes mellitus. Full‐length γ‐ENaC and α‐ENaC subunit abundances were not changed in kidney homogenates, but the 70 kDa γ‐ENaC cleavage product was increased in diabetic versus nondiabetic mice. CONCLUSIONS: Plasmin promotes hypertension in diabetes mellitus with albuminuria likely through the epithelial sodium channel. John Wiley and Sons Inc. 2020-11-20 /pmc/articles/PMC7763785/ /pubmed/33215566 http://dx.doi.org/10.1161/JAHA.120.016387 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Andersen, Henrik Hansen, Maria Høj Buhl, Kristian B. Stæhr, Mette Friis, Ulla G. Enggaard, Camilla Supramaniyam, Shanya Lund, Ida K. Svenningsen, Per Hansen, Pernille B. L. Jensen, Boye L. Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel |
title | Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel |
title_full | Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel |
title_fullStr | Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel |
title_full_unstemmed | Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel |
title_short | Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel |
title_sort | plasminogen deficiency and amiloride mitigate angiotensin ii–induced hypertension in type 1 diabetic mice suggesting effects through the epithelial sodium channel |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763785/ https://www.ncbi.nlm.nih.gov/pubmed/33215566 http://dx.doi.org/10.1161/JAHA.120.016387 |
work_keys_str_mv | AT andersenhenrik plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT hansenmariahøj plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT buhlkristianb plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT stæhrmette plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT friisullag plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT enggaardcamilla plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT supramaniyamshanya plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT lundidak plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT svenningsenper plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT hansenpernillebl plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel AT jensenboyel plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel |